Clinical trials: Choroidal Neovascular Membrane
Age Related Macular Degeneration, Choroidal Neovascular Membrane
A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial)
The purpose of this study is to determine whether 2.0mg Ranibizumab is effective in the treatment of recurrent fluid.
- Conditions
- Age Related Macular Degeneration, Choroidal Neovascular Membrane, Subfoveal Neovascular Age-Related Macular Degeneration, Macular Degeneration
- Trial name
- SAVE (NCT01025232)
- Testing
- Ranibizumab
- Where
- 2 sites in United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- David M. Brown, M.D.